Ann Duerr

Affiliate Professor, Epidemiology
Affiliate Professor, Global Health



PhD Biochemistry, Cell Biology, Massachusetts Institute of Technology, 1981
MD Medicine, Harvard University, 1985
MPH Epidemiology, Johns Hopkins University, 1988



Fred Hutchinson Cancer Research Center
Office E2-112
Box 358080
HIV Vaccine Trials Network
1100 Fairview Ave N
Seattle, WA 98109
View Website »


My current research focuses on early HIV detection and treatment to prevent onward HIV transmission among MSM in Peru and on multiple collaborations with laboratory scientists to study the implication of early treatment and substance use for future HIV cure strategies.
I hold appointments in Vaccine and Infectious Diseases, Clinical Research, and Public Health Sciences at the FHCRC and as an Affiliate Professor in the Departments of Epidemiology and Global Health at the University of Washington. I am Director of the Global Health Program of the Strategic Analysis Research and Training (START) Center. This collaborative program between the University of Washington and the Bill & Melinda Gates Foundation (BMGF) pairs graduate students with faculty mentors to provide applied experience for students and an academic-level research resource for the foundation. I also serve as an advisor to Ambassador Deborah Birx in the Office of the U.S. Global AIDS Coordinator and Health Diplomacy (OGAC) on the DREAMS Initiative, a partnership of OGAC with the BMGF and the Nike Foundation intended to reduce new HIV infections in girls and young women in 10 sub-Saharan countries.

Research Areas

Research Interests

Throughout her career, Dr. Duerr has been interested in public health issues of resource-limited settings, with a special emphasis on HIV and women's health. She trained in laboratory science, medicine, and infectious disease epidemiology - she received a B.Sc. degree from McGill University, a Ph.D. from Massachusetts Institute of Technology, an M.D. from Harvard University and an M.P.H. from Johns Hopkins University. For over 20 years, her research has focused on HIV. Her initial epidemiologic research focused on parameters associated with HIV transmission from women to infants in Rwanda and on fully characterizing the clinical course of HIV infections in US women. More recently, her work has been focused on prevention – specifically, on an intervention among African women to prevent mother-to-child HIV transmission via breastfeeding and on trials of prophylactic HIV vaccines as Director for Scientific Affairs of the HIV Vaccine Trials Network (HVTN). The HVTN is an international partnership of researchers with 25 sites on 4 continents conducting studies of the safety, immunogenicity, and efficacy studies of HIV vaccine candidates. She has also conducted research in non-human primates investigating ways to increase vaccine-induced immunity at mucosal surfaces, the site of infection for most pathogens.  She has a long-standing interest in clinical trials and is currently working on studies of antiretroviral treatment to prevent onward HIV transmission in Peru.  Her work in Peru also involves investigations of the impact of initiation of antiretroviral therapy (ART) during early HIV infection, including effects on neurological outcomes and implications for HIV cure strategies.

Recent Publications (PubMed)

Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
(2022 Sep)
PLoS Med 19(9): e1004097
Tapsoba JD, Cover J, Obong'o C, Brady M, Cressey TR, Mori K, Okomo G, Kariithi E, Obanda R, Oluoch-Madiang D, Chen YQ, Drain P, Duerr A

An Ethical Imperative to Ensure Uninterrupted HIV Care Following Therapeutic Trials: One Experience in Peru.
(2022 Jun)
AIDS Patient Care STDS 36(6): 205-207
Garcia-Rosales K, Sosa Barbaran K, Rios J, Pinto-Santini D, Del Rosario Leon M, Gallardo-Cartagena JA, MacRae J, Leon M, Valencia-HuamanĂ­ J, Montalban E, Gonzales P, Duerr A, Lama JR, Bender Ignacio R

Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance Use.
(2022 Jun)
Open Forum Infect Dis 9(6): ofac155
Gilada T, Schnittman SR, White E, Mercader J, Wang Y, Dasgupta S, Valdez R, Pinto-Santini D, Pasalar S, Sanchez J, Gonzales P, Lama JR, Bender Ignacio R, Duerr A

Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study.
(2021 May)
Lancet Microbe 2(5): e198-e209
Massanella M, Bender Ignacio RA, Lama JR, Pagliuzza A, Dasgupta S, Alfaro R, Rios J, Ganoza C, Pinto-Santini D, Gilada T, Duerr A, Chomont N, MERLIN Study Group.

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition.
PLoS One 17(5): e0267729
Bender Ignacio RA, Long J, Saha A, Nguyen FK, Joudeh L, Valinetz E, Mendelsohn SC, Scriba TJ, Hatherill M, Janes H, Churchyard G, Buchbinder S, Duerr A, Shah JA, Hawn TR

Show complete publication list

In the News

No news articles at this time.